Pfizer Inc
NYSE:PFE

Watchlist Manager
Pfizer Inc Logo
Pfizer Inc
NYSE:PFE
Watchlist
Price: 25.65 USD 2.07% Market Closed
Market Cap: 145.4B USD
Have any thoughts about
Pfizer Inc?
Write Note

Pfizer Inc
Other Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Pfizer Inc
Other Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Pfizer Inc
NYSE:PFE
Other Current Liabilities
$24.2B
CAGR 3-Years
-8%
CAGR 5-Years
12%
CAGR 10-Years
10%
Johnson & Johnson
NYSE:JNJ
Other Current Liabilities
$4.8B
CAGR 3-Years
31%
CAGR 5-Years
10%
CAGR 10-Years
12%
Bristol-Myers Squibb Co
NYSE:BMY
Other Current Liabilities
$4.8B
CAGR 3-Years
9%
CAGR 5-Years
24%
CAGR 10-Years
9%
Merck & Co Inc
NYSE:MRK
Other Current Liabilities
$7.2B
CAGR 3-Years
40%
CAGR 5-Years
24%
CAGR 10-Years
5%
Zoetis Inc
NYSE:ZTS
Other Current Liabilities
$238m
CAGR 3-Years
16%
CAGR 5-Years
29%
CAGR 10-Years
-8%
Eli Lilly and Co
NYSE:LLY
Other Current Liabilities
$5.6B
CAGR 3-Years
30%
CAGR 5-Years
21%
CAGR 10-Years
5%
No Stocks Found

Pfizer Inc
Glance View

Market Cap
145.4B USD
Industry
Pharmaceuticals

Pfizer Inc. is a global leader in the pharmaceutical industry, renowned for its commitment to innovative research and development that drives breakthroughs in healthcare. Founded in 1849, Pfizer has evolved into a powerhouse, particularly highlighted by its pivotal role in developing one of the first COVID-19 vaccines in collaboration with BioNTech. This achievement not only underscored the company's rapid response capabilities but also significantly boosted its revenue, showcasing its ability to pivot in times of global health crises. Investors are drawn to Pfizer not just for its historical legacy, but also for its diverse portfolio that includes treatments across various therapeutic areas such as oncology, immunology, and neurology, reflecting a balanced strategy poised for future growth. As Pfizer continues to navigate a post-pandemic world, its focus on innovation remains a cornerstone of its business strategy. With a robust pipeline of drugs in late-stage development and a strong commitment to mergers and acquisitions, Pfizer is determined to maintain market leadership while expanding its therapeutic offerings. Importantly, the company is also committed to shareholder value, consistently returning profits through dividends and share buybacks. For investors, Pfizer represents a compelling opportunity, merging stability with the potential for growth in an ever-evolving healthcare landscape, driven by advancements in science and technology.

PFE Intrinsic Value
24.05 USD
Overvaluation 6%
Intrinsic Value
Price

See Also

What is Pfizer Inc's Other Current Liabilities?
Other Current Liabilities
24.2B USD

Based on the financial report for Sep 29, 2024, Pfizer Inc's Other Current Liabilities amounts to 24.2B USD.

What is Pfizer Inc's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 10Y
10%

Over the last year, the Other Current Liabilities growth was 16%. The average annual Other Current Liabilities growth rates for Pfizer Inc have been -8% over the past three years , 12% over the past five years , and 10% over the past ten years .

Back to Top